US 10,376,484 B2
Combination of bezafibrate and of resveratrol or resveratrol derivatives for the treatment and prevention of diseases involving a mitochondrial energy dysfunction
Jean Bastin, Vitry sur Seine (FR); and Fatima Djouadi, Vitry sur Seine (FR)
Assigned to Institut National de la Santé et de la Recherche Médicale (INSERM), Paris (FR); and Universite Paris Descartes, Paris (FR)
Appl. No. 15/105,116
Filed by Institut National De La Santé Et De La Recherche Médicale (INSERM), Paris (FR); and Universite Paris Descartes, Paris (FR)
PCT Filed Dec. 19, 2014, PCT No. PCT/EP2014/078910
§ 371(c)(1), (2) Date Jun. 16, 2016,
PCT Pub. No. WO2015/092043, PCT Pub. Date Jun. 25, 2015.
Claims priority of application No. 13 63027 (FR), filed on Dec. 19, 2013.
Prior Publication US 2016/0317483 A1, Nov. 3, 2016
Int. Cl. A61K 31/05 (2006.01); A61K 31/195 (2006.01); A61K 31/7034 (2006.01)
CPC A61K 31/195 (2013.01) [A61K 31/05 (2013.01); A61K 31/7034 (2013.01)] 6 Claims
 
1. A method of therapeutic treatment of a disease involving mitochondrial energy dysfunction in a patient in need thereof, comprising administering to said patient effective amounts in combination 1) of bezafibrate and 2) of resveratrol, cis-resveratrol, dihydro-resveratrol, piceid or mixtures thereof, wherein said disease involving mitochondrial energy dysfunction is characterized by moderate deficiency in mitochondrial long-chain fatty acid β-oxidation due to the presence of at least one mutation on each allele of one of the genes encoding one of the following enzymes: CPT2, VLCAD, and LCHAD.